Literature DB >> 8499497

The impact of gender and age at onset on the familial aggregation of schizophrenia.

W Maier1, D Lichtermann, J Minges, R Heun, J Hallmayer.   

Abstract

Some recent family studies have shown that the familial risk for schizophrenia is higher in female than in male schizophrenics. It is debated whether the risks for the other disorders, such as schizotypal personality disorder or affective disorders in families of schizophrenics are similarly influenced by the proband's gender. Also, the reason for the effect of proband's gender on the recurrence risk for schizophrenia has not been clarified. This family study (159 probands, 589 first degree relatives) confirms that schizophrenia, but also schizophrenia spectrum disorders were more frequent in families of female compared with male schizophrenics. Neither age at onset in probands nor the interaction between gender and age at onset in probands had a relevant impact on the risk figures in relatives. Affective disorders occurred in families independently of the probands' gender. Aetiological heterogeneity or ascertainment bias may account for the modifying effect of proband's gender in schizophrenia.

Entities:  

Mesh:

Year:  1993        PMID: 8499497     DOI: 10.1007/BF02190387

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  19 in total

1.  Gender differences in the course of schizophrenia.

Authors:  J M Goldstein
Journal:  Am J Psychiatry       Date:  1988-06       Impact factor: 18.112

2.  How does gender influence age at first hospitalization for schizophrenia? A transnational case register study.

Authors:  H Häfner; A Riecher; K Maurer; W Löffler; P Munk-Jørgensen; E Strömgren
Journal:  Psychol Med       Date:  1989-11       Impact factor: 7.723

3.  Sex differences in the familial transmission of schizophrenia.

Authors:  J M Goldstein; S V Faraone; W J Chen; G S Tolomiczencko; M T Tsuang
Journal:  Br J Psychiatry       Date:  1990-06       Impact factor: 9.319

4.  The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures.

Authors:  L N Robins; J Wing; H U Wittchen; J E Helzer; T F Babor; J Burke; A Farmer; A Jablenski; R Pickens; D A Regier
Journal:  Arch Gen Psychiatry       Date:  1988-12

5.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

6.  The reliability of the SADS-LA in a family study setting.

Authors:  M Leboyer; W Maier; M Teherani; D Lichtermann; T D'Amato; P Franke; J P Lépine; J Minges; P McGuffin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 7.  Familial aggregation of schizophrenia and schizophrenia spectrum disorders. Evaluation of conflicting results.

Authors:  K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1988-04

8.  Family study of schizophrenia: exploratory analysis for relevant factors.

Authors:  L Bellodi; C Bussoleni; R Scorza-Smeraldi; G Grassi; L Zacchetti; E Smeraldi
Journal:  Schizophr Bull       Date:  1986       Impact factor: 9.306

9.  Gender, premorbid social functioning, and long-term outcome in DSM-III schizophrenia.

Authors:  S E Childers; C M Harding
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

10.  Gender and the course of schizophrenia: differences in treated outcomes.

Authors:  M C Angermeyer; L Kühn; J M Goldstein
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

View more
  9 in total

1.  Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method.

Authors:  N J Camp; S L Neuhausen; J Tiobech; A Polloi; H Coon; M Myles-Worsley
Journal:  Am J Hum Genet       Date:  2001-10-19       Impact factor: 11.025

2.  Heritability of schizophrenia and major affective disorder as a function of age, in the presence of strong cohort effects.

Authors:  Janice A Husted; Celia M T Greenwood; Anne S Bassett
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-12-05       Impact factor: 5.270

3.  The role of estrogen in schizophrenia.

Authors:  M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

4.  Resting neural activity distinguishes subgroups of schizophrenia patients.

Authors:  Dolores Malaspina; Jill Harkavy-Friedman; Cheryl Corcoran; Lilianne Mujica-Parodi; David Printz; Jack M Gorman; Ronald Van Heertum
Journal:  Biol Psychiatry       Date:  2004-12-15       Impact factor: 13.382

5.  Familial risks of psychotic disorders and schizophrenia among siblings based on hospitalizations in Sweden.

Authors:  Xinjun Li; Jan Sundquist; Kari Hemminki; Kristina Sundquist
Journal:  Psychiatry Res       Date:  2009-02-10       Impact factor: 3.222

6.  Age-specific familial risks of psychotic disorders and schizophrenia: a nation-wide epidemiological study from Sweden.

Authors:  Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Schizophr Res       Date:  2007-10-22       Impact factor: 4.939

7.  Family structure and risk factors for schizophrenia: case-sibling study.

Authors:  Jari K Haukka; Jaana Suvisaari; Jouko Lönnqvist
Journal:  BMC Psychiatry       Date:  2004-11-27       Impact factor: 3.630

8.  Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response.

Authors:  Alex Hatzimanolis; Pentagiotissa Stefanatou; Emmanouil Kattoulas; Irene Ralli; Stefanos Dimitrakopoulos; Stefania Foteli; Ioannis Kosteletos; Leonidas Mantonakis; Mirjana Selakovic; Rigas-Filippos Soldatos; Ilias Vlachos; Lida-Alkisti Xenaki; Nikolaos Smyrnis; Nicholas C Stefanis
Journal:  Eur Psychiatry       Date:  2020-04-29       Impact factor: 5.361

9.  Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.

Authors:  Susana Ochoa; Judith Usall; Jesús Cobo; Xavier Labad; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.